Table 1.
Demographic and Clinical Characteristics of 1141 Patients With COVID-19 at Mayo Clinic in the Midwest, May and June 2021a,b
| Characteristic | Casirivimab-imdevimab treatment (n=132) | No antibody treatment (n=1009) | P value |
|---|---|---|---|
| Age (y) | 55.6±15.9 | 44.8±18.0 | <.0001 |
| Male gender | 50.8 | 45.5 | .25 |
| Body mass index (kg/m2) | 34.3±8.4 | 30.9±7.2 | <.0001 |
| Medical comorbidities | |||
| Coronary artery disease | 12 (9.1) | 60 (6.0) | .18 |
| Congestive heart failure | 10 (7.6) | 36 (3.6) | .0316 |
| Chronic kidney disease | 12 (9.1) | 50 (5.0) | .052 |
| Diabetes | 28 (21.2) | 100 (9.9) | .0002 |
| Hypertension | 60 (45.5) | 188 (18.6) | <.0001 |
| Organ transplant | 4 (3.0) | 3 (0.3) | .0023 |
| Pulmonary disease | 21 (15.9) | 97 (9.6) | .0272 |
| Allocation criteria | |||
| CAST scorec | 3.1±1.9 | 1.8±1.8 | <.0001 |
| MASSd | 3.1±2.6 | 1.3±2.2 | <.0001 |
BMI = body mass index; CAST = COVID-19 Antibody Screening Tool; COVID-19 = coronavirus disease 2019; EUA = Emergency Use Authorization; FDA = Food and Drug Administration; MASS = Monoclonal Antibody Screening Score.
Data are presented as mean ± SD or as No. (percentage).
COVID-19 Antibody Screening Tool assigned 1 point to each of the expanded US FDA EUA criteria (released in May 2021) as follows: age ≥ 65 y, BMI ≥ 35 kg/m2, diabetes mellitus, hypertension, cardiovascular disease, pulmonary disease, dialysis or chronic kidney disease, bone marrow or organ transplant or immunosuppressive medication or disease, pregnancy, sickle cell disease, neurological or neurodevelopmental disorders, genetic or congenital metabolic disorder, liver disease, or use of medical devices.
Monoclonal Antibody Screening Score assigned a score to each of the original US FDA EUA criteria (released in November 2020) as follows: age ≥ 65 y (2), BMI ≥ 35 kg/m2 (2), diabetes mellitus (2), chronic kidney disease (3), cardiovascular disease in a patient 55 y and older (2), chronic respiratory disease in a patient 55 y and older (3), hypertension in a patient 55 y and older (1), and immunocompromised status (3). The maximum score is 18.